{"nctId":"NCT01535560","briefTitle":"Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa","startDateStruct":{"date":"2012-04"},"conditions":["Acute Otitis Externa"],"count":589,"armGroups":[{"label":"AL-60371","type":"EXPERIMENTAL","interventionNames":["Drug: AL-60371, 0.3% otic suspension"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: AL-60371 Vehicle"]}],"interventions":[{"name":"AL-60371, 0.3% otic suspension","otherNames":[]},{"name":"AL-60371 Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 6 months of age.\n* Clinical diagnosis of acute otitis externa (AOE) based on clinical observation and of presumed bacterial origin in at least one ear.\n* Combined numerical score of â‰¥4 in at least one affected ear at the Day 1 exam for tenderness, erythema, and edema.\n* Agree to refrain from water immersion of the ears during the conduct of the entire study.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Duration of signs or symptoms of AOE greater than 28 days in the affected ear(s) as reported by patient or parent/guardian.\n* Presence of a tympanostomy tube or perforated tympanic membrane in the affected ear(s).\n* Clinically diagnosed otic disease other than AOE (eg, malignant otitis externa) in the affected ear(s).\n* Known or suspected ear infection of yeast, fungal or mycobacterial origin in the affected ear(s).\n* Prior otologic surgery within 6 months of study entry in the affected ear(s).\n* Known or suspected allergy or hypersensitivity to quinolones or other ingredients present in the medications to be used in the study.\n* Patients who use ear plugs, head phones or ear buds and are unwilling to discontinue their use during the study period.\n* Other protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Months","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit","description":"An otoscopic exam was conducted by the physician. Clinical cure was considered attained if the sum of the numerical scores of the 3 signs and symptoms of AOE (tenderness, erythema, and edema) was 0 at Day 11. Proportion of patients is reported as percentage of participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.7","spread":null},{"groupId":"OG001","value":"40.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Microbiological Successes at the Day 11 (TOC) Visit","description":"Microbiological success was considered attained if all pre-therapy bacteria were absent from the exit otic specimen. The presence of fungi and/or yeast was not considered in the determination of microbiological success. Proportion of patients is reported as a percentage of participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Time (in Days) to Cessation of Ear Pain as Reported by the Patient or Parent/Legal Guadian Via the Telephone Diary","description":"Cessation of ear pain was defined as occurring the first time point that ear pain was absent (morning or evening) and did not reoccur in any subsequent diary entries.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"0.2"},{"groupId":"OG001","value":"6.5","spread":"0.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":274},"commonTop":[]}}}